<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002268</url>
  </required_header>
  <id_info>
    <org_study_id>071A</org_study_id>
    <secondary_id>Study No B102</secondary_id>
    <nct_id>NCT00002268</nct_id>
  </id_info>
  <brief_title>A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria</brief_title>
  <official_title>A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the safety, tolerance, and potential in vivo antiviral effects of five dosage&#xD;
      levels and a dose to be determined of human anti-cytomegalovirus (CMV) monoclonal antibody&#xD;
      (SDZ MSL-109; formerly SDZ 89-109) when administered once every 2 weeks for a total of 12&#xD;
      doses to patients with either AIDS or eligible AIDS-related complex (ARC) and with culture&#xD;
      proven evidence of CMV viremia and/or viruria. Sandoglobulin will be employed as a&#xD;
      comparative control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Cytomegalovirus Infections</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevirumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Acyclovir.&#xD;
&#xD;
          -  Experimental maintenance or prophylactic therapy with an approved therapeutic agent&#xD;
             for a non-viral opportunistic infection.&#xD;
&#xD;
          -  Trimethoprim / sulfamethoxazole (TMP / SMX).&#xD;
&#xD;
          -  Pyrimethamine / sulfadoxine.&#xD;
&#xD;
          -  Inhaled pentamidine.&#xD;
&#xD;
          -  Amphotericin B.&#xD;
&#xD;
          -  Ketoconazole.&#xD;
&#xD;
          -  Flucytosine (5-FC).&#xD;
&#xD;
          -  Antituberculosis therapy.&#xD;
&#xD;
          -  Recombinant human erythropoietin.&#xD;
&#xD;
          -  Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF).&#xD;
&#xD;
          -  Recombinant human interferon alfa 2 for AIDS-related Kaposi's sarcoma.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  AIDS or be HIV positive with CD4 lymphocyte counts below 200 cells/mm3 and be&#xD;
             receiving prophylaxis for Pneumocystis carinii pneumonia (PCP) (with or without&#xD;
             prophylaxis for another opportunistic infection), but have no prior medical history of&#xD;
             an opportunistic infection.&#xD;
&#xD;
          -  Expected survival of = or &gt; 6 months.&#xD;
&#xD;
          -  Willingness and ability to give written informed consent.&#xD;
&#xD;
          -  A copy of the signed and witnessed consent form must be maintained with the&#xD;
             investigator's study files.&#xD;
&#xD;
          -  Positive culture results documenting the presence of cytomegalovirus (CMV) viremia&#xD;
             and/or viruria.&#xD;
&#xD;
          -  Seropositive for the presence of circulating anti-CMV immunoglobulin.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Significant pulmonary dysfunction.&#xD;
&#xD;
          -  Uncontrolled or unstable diabetes.&#xD;
&#xD;
          -  Significant cardiovascular disease including uncontrolled hypertension, congestive&#xD;
             heart failure, cardiac arrhythmia, angina pectoris, or a history of myocardial&#xD;
             infarction within one year of entry into the study.&#xD;
&#xD;
          -  Coagulation or hemorrhagic disorders.&#xD;
&#xD;
          -  Any active severe opportunistic infection.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Therapy with ganciclovir (DHPG) or phosphonoformate (PFA) or other experimental&#xD;
             anti-cytomegalovirus therapy except as stipulated in this protocol.&#xD;
&#xD;
          -  Any other experimental antiviral therapy.&#xD;
&#xD;
          -  Biologicals including immunoglobulin therapy (except those patients randomized to&#xD;
             receive Sandoglobulin as specified in this protocol).&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Any significant organ system dysfunction as described in Exclusion co-existing&#xD;
             conditions.&#xD;
&#xD;
          -  Previous history of or evidence of idiopathic thrombocytopenia purpura,&#xD;
             agammaglobulinemia, or hypogammaglobulinemia.&#xD;
&#xD;
          -  Any other severe concomitant clinical condition.&#xD;
&#xD;
          -  Documented, active cytomegalovirus (CMV) disease (tissue or organ&#xD;
             invasion/dysfunction) at baseline. To this end, baseline indirect funduscopy (to&#xD;
             detect and exclude patients with peripheral CMV retinitis) will be performed.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Therapy with ganciclovir (DHPG) or phosphonoformate (PFA) or other experimental&#xD;
             anti-cytomegalovirus therapy except as stipulated in this protocol.&#xD;
&#xD;
          -  Any other experimental antiviral therapy.&#xD;
&#xD;
          -  Biologicals including immunoglobulin therapy (except those patients randomized to&#xD;
             receive Sandoglobulin as specified in this protocol).&#xD;
&#xD;
          -  Excluded:&#xD;
&#xD;
          -  Prior treatment with monoclonal antibodies derived from any animal species.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Major surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Galveston Med Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 1991</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Viremia</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

